<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Lipid Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Lipid Res</journal-id>
<journal-id journal-id-type="hwp">jlr</journal-id>
<journal-id journal-id-type="pmc">jlr</journal-id>
<journal-id journal-id-type="publisher-id">jlr</journal-id>
<journal-title-group>
<journal-title>Journal of Lipid Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-2275</issn>
<issn pub-type="epub">1539-7262</issn>
<publisher>
<publisher-name>The American Society for Biochemistry and Molecular Biology</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28292942</article-id>
<article-id pub-id-type="pmc">5454520</article-id>
<article-id pub-id-type="publisher-id">r075507</article-id>
<article-id pub-id-type="doi">10.1194/jlr.R075507</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Thematic Review Series</subject>
</subj-group>
<series-title>
<italic>Thematic Review Series: ApoE and Lipid Homeostasis in Alzheimer’s Disease</italic>
</series-title>
</article-categories>
<title-group>
<article-title>The ApoE receptors Vldlr and Apoer2 in central nervous system function and disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lane-Donovan</surname>
<given-names>Courtney</given-names>
</name>
<xref ref-type="aff" rid="aff1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herz</surname>
<given-names>Joachim</given-names>
</name>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff1">*</xref>
<xref ref-type="aff" rid="aff2">†</xref>
</contrib>
<aff id="aff1">Departments of Molecular Genetics and Neuroscience and Center for Translational Neurodegeneration Research,<label>*</label><institution>University of Texas Southwestern Medical Center</institution>, Dallas, <addr-line>TX</addr-line> 75390</aff>
<aff id="aff2">Department of Neurology and Neurotherapeutics,<label>†</label><institution>University of Texas Southwestern Medical Center</institution>, Dallas, <addr-line>TX</addr-line> 75390</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>1</label>To whom correspondence should be addressed. e-mail: <email>Joachim.herz@utsouthwestern.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>58</volume>
<issue>6</issue>
<fpage>1036</fpage>
<lpage>1043</lpage>
<history>
<date date-type="received">
<day>4</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>8</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement>
<copyright-year>2017</copyright-year>
</permissions>
<abstract>
<p>The LDL receptor (LDLR) family has long been studied for its role in cholesterol transport and metabolism; however, the identification of ApoE4, an LDLR ligand, as a genetic risk factor for late-onset Alzheimer’s disease has focused attention on the role this receptor family plays in the CNS. Surprisingly, it was discovered that two LDLR family members, ApoE receptor 2 (Apoer2) and VLDL receptor (Vldlr), play key roles in brain development and adult synaptic plasticity, primarily by mediating Reelin signaling. This review focuses on Apoer2 and Vldlr signaling in the CNS and its role in human disease.</p>
</abstract>
<kwd-group>
<kwd>apolipoproteins</kwd>
<kwd>Alzheimer’s disease</kwd>
<kwd>endocytosis</kwd>
<kwd>lipoprotein receptors</kwd>
<kwd>cell signaling</kwd>
<kwd>neurons</kwd>
<kwd>apolipoprotein E</kwd>
<kwd>very low density lipoprotein receptor</kwd>
<kwd>apolipoprotein E receptor 2</kwd>
</kwd-group>
<funding-group>
<award-group id="sp1">
<funding-source>
<institution-wrap>
<institution>National Institutes of Health</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100000002</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">F30-AG047799</award-id>
<award-id rid="sp1">HL063762</award-id>
<award-id rid="sp1">NS093382</award-id>
<award-id rid="sp1">AG053391</award-id>
</award-group>
</funding-group>
<funding-group>
<award-group id="sp2">
<funding-source>the Consortium for Frontotemporal Dementia Research</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group id="sp3">
<funding-source>
<institution-wrap>
<institution>BrightFocus Foundation</institution>
<institution-id institution-id-type="open-funder-registry">10.13039/100006312</institution-id>
</institution-wrap>
</funding-source>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>